|
Bayesian Re-Analysis of Clinical Trial Data
|
|
22
|
20638
|
January 27, 2022
|
|
Comparing Marginal effects across sets of explanatory variables in the same model
|
|
9
|
5194
|
January 1, 2022
|
|
Catastrophic Heterogeneity Meets "The Clairvoyant RCT"
|
|
0
|
2179
|
December 28, 2021
|
|
Nonparametric multiple linear regression (with interaction term and all !)
|
|
3
|
4568
|
December 18, 2021
|
|
Interpreting the random-effect solution in a mixed model
|
|
16
|
8574
|
December 18, 2021
|
|
How to achieve a pragmatic but correct interpretation of p values in null hypothesis significance testing framework NHST
|
|
1
|
3193
|
November 28, 2021
|
|
Recommendations of good methods examples in the biomarker literature
|
|
4
|
2592
|
November 23, 2021
|
|
Validity of comparing two different previously published cohort studies using IPTW for matching
|
|
5
|
2978
|
November 11, 2021
|
|
Interpretation of the REGEN-COV trial
|
|
22
|
11507
|
November 1, 2021
|
|
Probability in state Ps(t) and Hazard ratio HR in Cox model
|
|
1
|
2737
|
August 21, 2021
|
|
Logit Rank Plot by J.Copas in rms R package
|
|
6
|
3715
|
August 20, 2021
|
|
Resources for Mixed-Effect Models in Medical Contexts
|
|
5
|
3939
|
August 8, 2021
|
|
Question arising from JAMA Guide article "Odds Ratios—Current Best Practice and Use"
|
|
19
|
17584
|
July 13, 2021
|
|
Statistical Misinterpretations and Clinical Practice Guidelines: any examples?
|
|
31
|
14955
|
June 28, 2021
|
|
Calculating SMD from geometric mean titers
|
|
2
|
6373
|
May 26, 2021
|
|
The distinction between sample description (summarization) and point estimation
|
|
3
|
2428
|
May 9, 2021
|
|
Another null misinterpretation in a study about the association of epidural analgesia and offspring risk of autism
|
|
6
|
6248
|
May 1, 2021
|
|
Find skewness and kurtosis of a bivariate scatterplot
|
|
1
|
2810
|
March 29, 2021
|
|
Is there any intuition for the PRAUC metric?
|
|
0
|
2872
|
March 24, 2021
|
|
Recommended Reading: Pay No Atttention to the Model Behind the Curtain by Philip B. Stark
|
|
0
|
2992
|
March 11, 2021
|
|
Reporting Generalized Wilcoxon for Survival Analysis
|
|
6
|
4264
|
March 9, 2021
|
|
Musing on how to design "statistical functions/methods 2.0"
|
|
3
|
2205
|
March 7, 2021
|
|
Hazard-ratio of marginal effects?
|
|
1
|
3439
|
February 17, 2021
|
|
Early use of tocilizumab and steroids does not impact expansion or persistence of CAR T cells in B-ALL?
|
|
2
|
4127
|
February 17, 2021
|
|
Interpretation of P value
|
|
4
|
6825
|
December 31, 2020
|
|
Representative Covariate Settings
|
|
2
|
4358
|
December 27, 2020
|
|
Proper analysis and presentation of the association between a continuous exposure and a binary outcome
|
|
1
|
3741
|
November 8, 2020
|
|
Can treatment B be superior after the RCT if it was thought that treatment A is superior before the RCT?
|
|
5
|
3598
|
October 13, 2020
|
|
Time since randomization and causality
|
|
2
|
2524
|
September 27, 2020
|
|
Bayesian Solutions for Challenges to Frequentist Statistics
|
|
0
|
6452
|
September 22, 2020
|